4. Comparison of median survival: cisplatin combination including or excluding a taxane.
Study | Cisplatin + other | Cisplatin + taxane | P value | ||||
n | Median OS (months) |
Median PFS (months) |
n | Median OS (months) |
Median PFS (months) |
||
Monk 2008 CV vs. CT vs. CG vs. CP |
117 (CV) 118 (CT) 119 (CG) |
10‐10.3 | 4.9 (CV) 4.6 (CT) 4.7 (CG) |
118 (CP) | 12.9 | 5.8 | ns |
Mountzios 2009 CI vs. CIP |
74 (CI) | 13.2 | 6.3 | 79 (CIP) | 15.4 | 7.9 | 0.048 (OS) 0.023 (PFS) |
CG: cisplatin/gemcitabine; CI: cisplatin/ifosfamide; CIP: cisplatin/ifosfamide/paclitaxel; CP: cisplatin/paclitaxel; CT: cisplatin/topotecan; CV: cisplatin/vinorelbine; OS: overall survival; PFS: progression‐free survival; ns: not significant